Board summary
Key figures
74,776
Registered population
57.4% aged 18–64
23.9%
Aged 65+
ICB 19.0% · England 17.9%
3.4%
Ethnic minority (non-White)
1.3% Asian · England 9.6%
4.4%
In IMD quintile 1
ICB 31.9% · England 21.0%
~3,117
Core20 residents (est.)
Resident basis; registered basis ~3,318 · see page 3
13,630
Hypertension register
+5.23% in 3 yrs · England +5.60%
678
SMI register
17.1% of Cheshire East (LAD)'s
1,412
COPD register
Reviews -3.42% in 3 yrs
Forecast to 2030
15,897
Hypertension patients, 2030
+2,267 on today
58.6%
QRISK ≥20% on statins, 2030
+1.13pp over 3 yrs
5.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail comparators.
Annual asthma reviews reach 61.0% (Cheshire East (LAD) 64.5%, ICB 62.3%, England 65.7%), leaving an estimated 1,993 of 5,115 registered patients unreviewed.
High-risk lipid therapy and SMI checks lag.
Lipid-lowering therapy is 56.3% for QRISK ≥ 20% (England 63.6%) and 60.9% for CKD (England 70.3%), while SMI BP checks reach 77.1% (England 83.4%).
Breast and cervical screening exceed benchmarks.
Breast screening aged 53 to 70 is 74.6% (England 69.9%) after +11.3% three-year growth (England +8.4%), alongside 78.3% cervical screening aged 25-49 (England 66.8%).
Population, age and ethnicity
With 23.9% aged 65+, the PCN serves an older population than national averages
Across 74,776 registered patients, 23.9% (17,898) are aged 65+, above Cheshire East (22.6%), NHS Cheshire and Merseyside ICB (19.0%) and England (17.9%). Based on Census usual residents rather than registered patients, 96.6% identify as White (Cheshire East 94.4%, ICB 93.0%, England 81.1%), with an ethnic minority share of 3.4% (Asian 1.3%, Mixed 1.3%, Black 0.4%). Projected population growth to 2030 is 3.8% under unverified methodology (Cheshire East 3.4%, ICB 2.3%, England 2.3%). This older age demographic may concentrate chronic disease and frailty workload across the network's seven practices.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Cheshire East LA) | 2,129 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 75.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.3% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Cheshire East LA) | 939 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Cheshire East LA) | 14.8 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Low overall deprivation conceals Core20 exposure spanning 10.2 pp across practices
Overall deprivation is low, with an average IMD decile of 7.7 and 4.4% of registered patients in the Core20 cohort, compared with 9.2% in Cheshire East (LAD), 31.9% in the ICB, and 21.0% in England. Core20 exposure spans 10.2 pp across practices. Concentration is highest at Merepark Medical Centre (10.2%) and Oaklands (10.0%), whereas volume centres on Oaklands (1,180 estimated patients) and The Cedars Medical Centre (1,005 patients). Ashfields Primary Care Centre, Haslington Surgery, and Greenmoss Medical Centre record 0.0%.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
678
SMI register
0.91% recorded prevalence
299
Learning disability register
0.40% recorded prevalence
18
Care homes, 769 beds
In the PCN catchment
8.8%
Provide unpaid care
Cheshire East (LAD), Census 2021
SMASH PCN records 678 severe mental illness patients (0.9%; Cheshire East 0.9%, NHS Cheshire and Merseyside ICB 1.1%, England 1.0%) and 299 with learning disabilities (0.4%; Cheshire East 0.5%, ICB 0.6%, England 0.6%), alongside 18 catchment care homes with 769 beds. Lower recorded prevalence may reflect coding or ascertainment variation rather than lower need, which clinical register audits would test.
Severe mental illness: physical health checks
SMI annual blood pressure checks reached 77.1% (Cheshire East (LAD) 79.0%, England 83.4%), falling 1.1 pp over three years (2023 to 2025; England +4.4 pp). Recorded BMI reached 82.6% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
13,630
Hypertension register
+5.23%
Register growth, 3 yrs
Cheshire East (LAD) +6.54% · England +5.60%
−2.14pp
BP control, under 80
≤140/90 · −1.67pp aged 80+
+2,267
More patients by 2030
Forecast 15,897 (20.26%)
Hypertension case-finding and control
Hypertension recorded prevalence is 18.3% (13,630 patients), above Cheshire East (LAD) (17.3%), the ICB (16.8%) and England (15.2%). While 68.6% of patients aged under 80 achieve blood pressure control to <= 140/90 mmHg (England 67.8%), control fell 3.0% over three years (2023 to 2025; England +3.2%). Practice prevalence ranges from 15.4% at Waters Edge Medical Centre to 24.7% at Greenmoss Medical Centre.
Lipids and statins
At 56.3%, QRISK ≥ 20% lipid-lowering therapy trails Cheshire East (LAD) (61.2%), NHS Cheshire and Merseyside Integrated Care Board (63.2%) and England (63.6%), while CKD lipid therapy is 60.9% (England 70.3%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 130,902 | £1.80 | £1.71 | £1.86 | £235,624 |
| Cardiovascular (all), 2025 | 201,218 | £4.14 | £4.37 | £3.33 | £833,043 |
In 2026, 130,902 lipid-regulating drug items cost £1.80 each (Cheshire East (LAD) £1.72, NHS Cheshire and Merseyside Integrated Care Board £1.71, England £1.86), totalling £235,624. Spend was £7,854 less than at England's unit cost, but £11,781 more than at NHS Cheshire and Merseyside Integrated Care Board's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−0.07%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.01%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.3% (5,115 patients; England 6.6%, Cheshire East (LAD) 6.9%), yet only 61.0% had an annual review (England 65.7%, Cheshire East (LAD) 64.5%), leaving an estimated 1,993 registered patients unreviewed. COPD prevalence is 1.9% (1,412 patients; England 1.9%), but 12-month reviews fell 3.4% over three years (2023 to 2025; England +2.8%) to 73.0% (England 76.4%). Prescribing for ages 5-19 is 1,483 items per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer register prevalence is 5.2% (3,841 patients; England 3.8%, Cheshire East (LAD) 4.9%). For childhood immunisations, MMR dose 1 at age 5 reaches 94.9% (England 91.7%), but MMR dose 2 drops 3.1 pp to 91.8% (England 82.8%), trailing the 95.0% target by 3.2 pp. Additionally, 4-in-1 booster coverage at age 5 is 89.8% (England 80.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, across NHS Cheshire and Merseyside ICB, 55.5% of cancers with a known stage (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%). Known-stage status was recorded for 72.8% of registered cancers (13,490 of 18,522; England 67.0%). Reaching the 75.0% national ambition would require about 2,640 extra early-stage diagnoses a year across the ICB. Meanwhile, SMASH PCN's cancer register grew +7.1% over three years (2023 to 2025), trailing Cheshire East (LAD) (+10.6%) and England (+9.0%). ICB stage data reflects wider system pathways rather than PCN performance; site-specific small numbers warrant caution, while trailing PCN register growth may reflect practice-level identification variations, unverified locally.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Mid Cheshire Hospitals NHS Foundation Trust achieved 80.0% on the 28-day faster diagnosis standard, meeting the 75.0% target and exceeding the ICB (77.2%) and England (79.3%), while East Cheshire NHS Trust reached 81.1% and University Hospitals of North Midlands NHS Trust achieved 80.6%. On the 62-day referral to treatment standard, Mid Cheshire Hospitals achieved 71.1%, trailing the 85.0% standard and the ICB (76.2%) but in line with England (71.2%), ahead of East Cheshire NHS Trust (53.4%) and University Hospitals of North Midlands NHS Trust (68.8%). These provider metrics describe acute system performance rather than PCN delivery.
| Pathways within standard (%) | Mid Cheshire | of North Midlands | East Cheshire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 79.95 | 80.65 | 81.08 | 77.25 | 79.32 |
| 31-day treatment (96%) | 86.21 | 93.85 | 96.30 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 71.12 | 68.84 | 53.41 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Mid Cheshire | of North Midlands | East Cheshire | England |
|---|---|---|---|---|
| MRI | 5.15 | 36.13 | 26.62 | 21.40 |
| CT | 1.09 | 2.86 | 11.49 | 9.92 |
| Echocardiography | 5.51 | 45.39 | 26.24 | 28.48 |
| Colonoscopy | 30.34 | 46.53 | 10.85 | 30.83 |
| Gastroscopy | 31.89 | 15.49 | 10.25 | 29.02 |
| All 15 DM01 tests | 12.72 | 22.94 | 16.17 | 23.14 |
| Community services activity | Cheshire East residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 72,825 | 541,280 |
| Referrals | 18,280 | 97,150 |
| Patients with a contact | 21,910 | 146,240 |
Community services (residents of Cheshire East), Jun 2026 (provisional). In Jun 2026 (provisional), adults aged 65 and over accounted for 60.8% of community health service contacts among Cheshire East local authority residents (44,295 of 72,825 total contacts). Provider-level community data was not captured. These borough resident figures indicate heavy older-age community service reliance, though they cannot establish activity or reach for SMASH PCN registered patients.
Practice variation and patient experience
Practice variation and patient experience
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Cedars | 110 | 8.4 | 72.8% | 81.0% | 90.2% |
| Ashfields Primary | 149 | 0.0 | 66.4% | 82.0% | 86.6% |
| Oaklands | 120 | 10.0 | 70.7% | 63.2% | 85.0% |
| Greenmoss | 114 | 0.0 | 87.6% | 78.0% | 85.0% |
| Merepark | 105 | 10.2 | 56.1% | 78.4% | 80.6% |
| Waters Edge | 120 | 8.1 | 77.7% | 76.3% | 78.0% |
| Haslington Surgery | 103 | 0.0 | 71.2% | 87.4% | 72.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Three-year chronic disease trajectories lagged England across diabetes, hypertension and respiratory care
Over three years, the PCN lagged England's trajectory in diabetes HbA1c control without frailty (-2.0% vs England +4.4%), blood pressure control under age 80 (-3.0% vs England +3.2%), and COPD reviews (-3.4% vs England +2.8%). Mental health register blood pressure checks fell 1.1 pp (England +4.4 pp). By contrast, three-year breast screening coverage increased +11.3% (England +8.4%) to 74.6% (England 69.9%), and smoking cessation offers rose +0.5 pp (England +0.1 pp) to 96.5% (England 94.2%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Diabetes HbA1c control
BP control, under 80
COPD reviews
Hypertension treated to target
BP check (SMI)
Breast screening (53-70)
Smoking support (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Cheshire East (LAD) | Asset | PCN | Cheshire East (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (769 beds) | n/a | Schools (catchment) | 69 | n/a |
| Children's centres | 3 | 14 | Places of worship | 64 | 272 |
| Libraries | 3 | 16 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 8 | 41 | Primary academies | 19 | 78 |
| Special schools | 2 | 5 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma annual review coverage is 61.0% (Cheshire East (LAD) 64.5%, ICB 62.3%, England 65.7%, denominator includes PCAs), leaving 1,993 of 5,115 registered patients unreviewed. For discussion: practices could run structured single-template recall and flexible review slots alongside inhaler prescribing checks, starting in higher-Core20 practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
High-risk lipid and BP escalation
QRISK ≥ 20% lipid therapy is 56.3% (Cheshire East (LAD) 61.2%, ICB 63.2%, England 63.6%) and CKD lipid therapy is 60.9% (England 70.3%), while <80 BP control 3-year change is -3.0%. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Combined SMI physical health checks
On the 678-patient SMI register (0.9% prevalence), 12-month BP checks are 77.1% (Cheshire East (LAD) 79.0%, ICB 81.3%, England 83.4%, incl. PCAs) after falling 1.1 pp over 3 years. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Learning disability register review (p2) | Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI blood pressure recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Cardiovascular review and titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR catch-up (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer register recording review (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · High-risk lipid and BP escalation (p12) | Hypertension register · Hypertension: QOF prevalence · Patients with QRISK ≥ 20% treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Combined SMI physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
